Tirzepatide for Excess Weight in Adults With Type 1 Diabetes Using MiniMed 780G.
Tirzepatide isn’t just making noise in type 2 diabetes anymore. Researchers in Italy just ran a study looking at tirzepatide for excess weight in adults with type 1 diabetes using the MiniMed 780G closed-loop insulin pump. The results? Tirzepatide showed real promise for tackling weight management in this group, a space that’s notoriously tricky.
Diabetes Obes Metab
by De Fano M, Tortoriello R, Rucco S et al.
“Tirzepatide for Excess Weight in Adults With Type 1 Diabetes Using MiniMed 780G. De Fano M(1), Tortoriello R(1), Rucco S(1), Corio S(1), Manco M(1), Guerrini E(1), Porcellati F(1). Author information: (1)Endocrine and Metabolic Sciences Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.”
Type 1 diabetes researchers know the drill: insulin therapy can make weight loss feel impossible. Most weight loss drugs aren’t studied in this population, let alone peptide-based therapies. But tirzepatide—a dual GIP/GLP-1 receptor agonist—has already shaken up obesity and type 2 diabetes research. Now, it’s starting to get attention in type 1.
Here’s what stood out:
Adults with type 1 diabetes using the MiniMed 780G system saw meaningful weight loss while taking tirzepatide.
The closed-loop insulin delivery wasn’t disrupted—glucose management stayed on track.
The research suggests tirzepatide could be a valuable tool for weight issues in type 1, not just type 2.
Key takeaway: tirzepatide is breaking out of its old boxes. Researchers should pay attention to peptide therapies for weight management across diabetes types, not just the usual suspects. If you’re sourcing tirzepatide for research, check the tirzepatide page for more details or browse the vendor directory.
The peptide field keeps moving fast—this study is another sign that researchers are thinking bigger.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.